Children born with certain congenital heart defects face a harsh reality. Many need pulmonary valve replacement early in life. Yet the valves available until now don’t grow with them. That forces repeated open-heart surgeries. Doctors time the first operation carefully. Intervene too soon and the child may need three or more procedures before adulthood. Wait too long and the heart suffers damage.

On October 1, 2026, the FDA changed that calculation. It approved the Autus Size-Adjustable Valve from Edwards Lifesciences. The device is the first surgically implanted pulmonary heart valve designed to expand after implantation. It starts small enough for a toddler. Later it widens via a minimally invasive balloon procedure. No new chest incision required.

The Challenge of Pediatric Valve Replacement

Traditional valves come in fixed sizes. They use animal tissue for the leaflets that open and close with each heartbeat. In children that tissue hardens and breaks down faster than in adults. The mismatch grows worse as the patient gets taller and the heart chamber enlarges. Surgeons have managed with homografts from human donors or bioprosthetic valves. Both approaches often lead to reoperation every few years.

The Autus valve takes a different approach. It deploys as small as 13 millimeters in diameter. That fits toddlers and preschoolers. Over time doctors widen it with a balloon catheter up to 22 millimeters. That’s adult size. The expansion happens in a catheterization lab. Recovery is quicker. Risks drop. Families avoid the emotional and physical toll of multiple sternotomies.

And the material marks another first. The leaflets are made from a synthetic polymer instead of cow or pig tissue. Animal-derived valves calcify rapidly in young patients. One-year follow-up data from the pivotal trial suggest the polymeric leaflets hold up well. This approval represents the first time the FDA has cleared any heart valve using polymeric leaflet material.

The agency based its decision on a single-arm study of 62 pediatric patients at 12 U.S. sites. Ages ranged from 18 months to 16 years. All needed pulmonary valve replacement due to congenital disease. Results impressed. One hundred percent of patients stayed free from device-related complications in the first 30 days. No deaths. No strokes. No blood clots needing extra treatment.

At six months the first 60 patients showed acceptable blood flow through the right side of the heart. Leakage stayed at mild or less. Those who reached one year maintained a right ventricular outflow tract mean gradient of 40 mm Hg or lower. No patient needed valve reintervention. Follow-up will continue for a full decade. Long-term durability remains the key unknown.

“For children born with congenital heart disease, valve replacement timing has always been a difficult decision — wait too long and you risk harm to the child, but intervene too early and they may need multiple open-heart surgeries as they grow,” said Michelle Tarver, MD, PhD, director of the FDA’s Center for Devices and Radiological Health, in the FDA announcement. “The Autus Size-Adjustable Valve gives doctors the option of far fewer trips to the operating room, which may result in better quality of life for these children and their families.”

Emile Bacha, MD, a study author and chief of cardiac surgery at NewYork-Presbyterian/Columbia University Irving Medical Center, echoed that sentiment. He noted that children with congenital pulmonary valve disease have long needed prosthetics that account for growth. The new option could reshape planning for these cases.

Edwards Lifesciences acquired the technology earlier this year. The company bought Autus Valve Technologies for $128.9 million plus potential milestones. Before that it had paid $11.5 million for an option to buy. The deal brought a promising pediatric platform into Edwards’ structural heart portfolio. CEO Bernard Zovighian highlighted the firm’s long focus on complex conditions. “The Autus valve represents a meaningful advancement for children who have historically had limited treatment options,” he said in the MassDevice report.

Recent coverage adds context. A MedPage Today article published the same day emphasized the valve as the only surgical pulmonary option specifically fit for growing kids. It also noted the polymeric leaflets may prove more durable than animal tissue. Healio reported consistent outcomes through one year with less than moderate regurgitation and zero reinterventions. These pieces, drawing from the same FDA data, underscore the trial’s clean safety profile.

Congenital heart defects affect about 1 in 100 U.S. births. Pulmonary valve problems form a significant subset. Many patients with tetralogy of Fallot, pulmonary atresia or truncus arteriosus eventually need valve replacement. Until now the standard carried a heavy burden. Multiple surgeries mean repeated anesthesia exposure, scar tissue buildup, infection risk and days away from school. Parents shoulder years of worry.

The Autus device received Breakthrough Device designation. It also participated in the FDA’s Total Product Life Cycle Advisory Program. Both programs aim to speed promising technologies for unmet needs. Approval came through the premarket approval pathway. That’s the agency’s strictest review for devices.

Still, questions linger. Will the valve expand reliably at every stage of childhood? How many dilations can it tolerate before performance drops? What happens beyond five or ten years? The polymeric material looks promising in early data. Yet real-world experience will decide if it resists calcification and tearing better than bovine pericardium over a child’s active life.

Edwards plans a controlled rollout. Congenital heart surgeons already familiar with balloon-expandable valves will adopt first. Centers like University of Michigan Health C.S. Mott Children’s Hospital, which implanted the valve during the trial, bring early expertise. Jennifer Romano, MD, led one of the key sites there.

So the approval lands at a moment of measured optimism. Pediatric cardiologists and surgeons now have a tool that aligns better with physiology. Fewer operations. Less trauma. The possibility of a single early implant that lasts into the teenage years or beyond. But success depends on careful patient selection and continued follow-up.

One fact stands clear. For the first time, doctors don’t have to choose between operating too early or letting the heart strain. The valve can grow with the child. That small shift carries large implications for thousands of families each year.